Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. AJP. 2013;170:324–33.

Article  Google Scholar 

Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211:175–81.

Article  PubMed  PubMed Central  Google Scholar 

Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47:1549–56.

Article  PubMed  Google Scholar 

Kowal C, Peyre H, Amad A, Pelissolo A, Leboyer M, Schürhoff F, et al. Psychotic, mood, and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis. Psychosom Med. 2020;82:838–49.

Article  PubMed  Google Scholar 

Veeneman RR, Vermeulen JM, Abdellaoui A, Sanderson E, Wootton RE, Tadros R, et al. Exploring the relationship between schizophrenia and cardiovascular disease: a genetic correlation and multivariable mendelian randomization study. Schizophr Bull. 2022;48:463–73.

Article  PubMed  Google Scholar 

Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Næss Ø, Ystrom E, et al. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand. 2019;139:558–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szöke A, Pignon B, Godin O, Ferchiou A, Tamouza R, Leboyer M, et al. Multimorbidity and the etiology of schizophrenia. Curr Psychiatry Rep. 2024;26:253–63.

Article  PubMed  Google Scholar 

Huang K-L, Fang C-J, Hsu C-C, Wu S-I, Juang JJ, Stewart R. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol. 2017;31:1544–55.

Article  PubMed  Google Scholar 

Ferraris A, Szmulewicz AG, Posadas-Martínez ML, Serena MA, Vazquez FJ, Angriman F. The effect of antipsychotic treatment on recurrent venous thromboembolic disease: a cohort study. J Clin Psychiatry. 2019;80(5):18m12656.

Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, et al. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacol. 2022;47:664–72.

Article  Google Scholar 

Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771–81.

Article  CAS  PubMed  Google Scholar 

Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19:96.

Article  PubMed  PubMed Central  Google Scholar 

Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28:887–920.

Article  CAS  PubMed  Google Scholar 

Carrà G, Crocamo C, Bartoli F, Lax A, Tremolada M, Lucii C, et al. First-generation antipsychotics and QTc: any role for mediating variables? Hum Psychopharmacol Clin Exp. 2016;31:313–8.

Article  Google Scholar 

Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, et al. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. Psychopharmacology. 2023;240:199–202.

Article  CAS  PubMed  Google Scholar 

El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 2018;41:414–21.

Article  PubMed  Google Scholar 

Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram. Circulation. 2009;119:e241–50.

Article  PubMed  Google Scholar 

Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67:1639–50.

Article  PubMed  Google Scholar 

Li S, Xu C, Hu S, Lai J. Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. Eur Psychiatry. 2024;67: e29.

Article  PubMed  PubMed Central  Google Scholar 

Jha MK, Mathew SJ. Pharmacotherapies for treatment-resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape. Am J Psychiatry. 2023;180:190–9.

Article  PubMed  Google Scholar 

Tajika A, Hori H, Iga J, Koshikawa Y, Ogata H, Ogawa Y, et al. Mood stabilizers and antipsychotics for acute mania: systematic review and meta-analysis of augmentation therapy vs monotherapy from the perspective of time to the onset of treatment effects. Int J Neuropsychopharmacol. 2022;25:839–52.

Article  PubMed  PubMed Central  Google Scholar 

Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–52.

Article  CAS  PubMed  Google Scholar 

Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107:85–95.

Article  CAS  PubMed  Google Scholar 

Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62–9.

Article  CAS  PubMed  Google Scholar 

Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.

Article  CAS  PubMed  Google Scholar 

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Åström-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587–92.

Article  PubMed  Google Scholar 

Piotrovsky V. Pharmacokinetic–pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 2005;7:E609-624.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047–60.

Article  PubMed  PubMed Central  Google Scholar 

Schürhoff F, Fond G, Berna F, Bulzacka E, Vilain J, Capdevielle D, et al. A national network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap. Eur Psychiatry. 2015;30:728–35.

Article  PubMed  Google Scholar 

Pignon B, Lajnef M, Godin O, Geoffray M-M, Rey R, Mallet J, et al. Relationship between childhood trauma and level of insight in schizophrenia: a path-analysis in the national FACE-SZ dataset. Schizophr Res. 2019;208:90–6.

Article  PubMed  Google Scholar 

Fond G, Godin O, Schürhoff F, Berna F, André M, Aouizerate B, et al. Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2020;101: 109927.

Article  CAS  PubMed  Google Scholar 

Szöke A, Richard J-R, Fond G, Misdrahi D, Lajnef M, Aouizerate B, et al. Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia—data from the FACE-SZ cohort. J Psychiatr Res. 2023;161:206–12.

Article  PubMed